Antibody Drug Conjugates (ADCs) are a novel class of therapeutics designed to deliver cytotoxic drugs specifically to cancer cells. They consist of three main components: a monoclonal antibody that targets a specific antigen on cancer cells, a cytotoxic drug (also known as the payload), and a linker that connects the two. This targeted approach aims to minimize damage to healthy cells and reduce side effects compared to traditional chemotherapy.
